Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
Major Deal For ‘Gene Traffic Control’ Company
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
You may also be interested in...
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.